Myeloproliferative Neoplasms | Specialty

The myeloproliferative neoplasms condition center is a comprehensive resource for clinical news on myeloproliferative neoplasms. Read more at OncLive.

Oral and Subcutaneous Azacitidine Show Comparable PK, Safety Profiles in MDS and CMML

December 11th 2025

Oral azacitidine demonstrated a similar pharmacokinetic and safety profile to the subcutaneous formulation in MDS or CMML.

Nuvisertib Plus Momelotinib Is Safe, Produces Spleen, Symptom, Anemia Responses in R/R Myelofibrosis

December 10th 2025

Nuvisertib demonstrated clinical activity as both a single agent and in combination with momelotinib for patients with relapsed/refractory myelofibrosis.

AJ1-11095 Receives Orphan Drug Designation From the FDA in Myelofibrosis

December 10th 2025

AJ1-11095 received orphan drug designation from the FDA in myelofibrosis.

Pelabresib Plus Ruxolitinib Bests Ruxolitinib Monotherapy in JAK Inhibitor-Naive Myelofibrosis

December 9th 2025

Pelabresib plus ruxolitinib improved primary and secondary efficacy end points vs ruxolitinib alone in JAK inhibitor-naive myelofibrosis.

INCA033989 Nets FDA Breakthrough Therapy Designation in CALR-Mutated R/R Essential Thrombocythemia

December 8th 2025

The FDA has granted breakthrough therapy designation to INCA033989 in CALR-mutated essential thrombocythemia.

INCA033989 With/Without Ruxolitinib Is Safe, Drives Spleen and Anemia Responses in CALR Exon 9–Mutated Myelofibrosis

December 7th 2025

INCA033989 given with or without ruxolitinib was well tolerated and yielded spleen and anemia responses in myelofibrosis with CALR exon 9 mutations

Oral Decitabine/Cedazuridine Plus Venetoclax Yields 91% ORR in High-Risk MDS and CMML

December 7th 2025

Decitabine/cedazuridine plus venetoclax produced a 91% response rate and 30-month median OS in high-risk MDS/CMML.

Rusfertide Continues to Show Strong Results for Polycythemia Vera

December 6th 2025

Rusfertide sustained hematocrit control and sharply reduced phlebotomy need through week 52 in PV, showing durable efficacy and a consistent safety profile.

Dr Desai on Future Research Directions in MPN and Other Hematologic Malignancies

December 5th 2025

Ruchi J. Desai, MD, discusses future research directions in MPN and other hematologic malignancies.

All Eyes Are on Novel Combination Therapies and Molecular Targets in MPN at ASH 2025

December 5th 2025

Ahead of the 2025 ASH Annual Meeting, experts in myeloproliferative neoplasms share the most anticipated research being presented during the meeting.

Dr Desai on the Use of JAK Inhibitors in Myeloproliferative Neoplasms

November 28th 2025

Ruchi J. Desai, MD, discusses the current standing of JAK inhibitors in the treatment landscape of myeloproliferative neoplasms.

Dr Desai on Notable Ongoing Studies in Myeloproliferative Neoplasms

November 26th 2025

Ruchi J. Desai, MD, discusses several notable ongoing studies examining agents for the treatment of patients with myeloproliferative neoplasms.

Dr Desai on the Treatment Landscape of Polycythemia Vera

November 14th 2025

Ruchi J. Desai, MD, discusses the treatment landscape of polycythemia vera and unmet needs in the space.

JAK Inhibitor Selection and Sequencing Strategies Are Key in Myelofibrosis Management

November 5th 2025

Akriti Jain, MD, discusses treatment selection and sequencing of JAK inhibitors in myelofibrosis, emerging CALR-targeted research, and defining disease modification.

JAK Inhibitors Expand Treatment Options in Polycythemia Vera and Myelofibrosis

November 4th 2025

Akriti Jain, MD, highlights the evolving role of JAK inhibitors in managing polycythemia vera and myelofibrosis and efforts to optimize treatment sequencing.

Meta Analysis Highlights Benefits of JAK Inhibitors vs BAT in Myelofibrosis

November 3rd 2025

Findings from a meta analysis showed that JAK inhibitors were associated with improved outcomes vs best available therapy in myelofibrosis.

Five Under 5: Top Oncology Videos for the Week of 10/26

November 2nd 2025

The top 5 OncLive TV videos of the week cover insights in myeloproliferative neoplasms, lung cancer, ovarian cancer, and prostate cancer.

Dr Jain on Persisting Gaps in Defining Disease Modification in Polycythemia Vera and Myelofibrosis

October 27th 2025

Akriti G. Jain, MD, detailed the current unmet needs in polycythemia vera and myelofibrosis, including how to define disease modification.

The OncFive: Top Oncology Articles for the Week of 10/19

October 25th 2025

The FDA has cleared BVd for multiple myeloma and revumenib for NPM1-mutant AML, and granted priority review to perioperative enfortumab vedotin in MIBC.

Dr Gerds on Notable Ongoing Clinical Trials in Myelofibrosis

October 21st 2025

Aaron T. Gerds, MD, MS, discusses clinical trials to watch in the evolving myelofibrosis research paradigm.